Clinical trials: Migraine, Acute
Migraine Disorders
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
An evaluation of tablet disintegration and absorption and gastric transit of sumatriptan and naproxen sodium from a TREXIMA tablet and eletriptan from a RELPAX 40mg tablet.
- Trial name
- NCT00385008
- Testing
- Combination Product (sumatriptan succinate / naproxen sodium), RELPAX(eletriptan) 40mg Tablet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Migraine
AVPI Migraine Study
The study is designed as a multicenter, double-blind, randomized, sham-controlled trial to assess the safety and effectiveness of the Nocira AVPI Device for the acute treatment of migraine.
- Trial name
- NC06 (NCT05537818)
- Testing
- AVPI Device
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Nocira, LLC
Migraine
Maximizing Outcomes in Treating Acute Migraine
AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults.
- Trial name
- MOMENTUM (NCT03896009)
- Testing
- AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam, Rizatriptan
- Where
- 85 sites in United States
- Volunteers
- 1,594 people
- Sponsor
- Axsome Therapeutics, Inc.
Migraine, Acute Treatment of Migraine
Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711) compared with placebo in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level reported as "no pain")…
- Trial name
- NCT01430442
- Testing
- Rimegepant, Sumatriptan
- Where
- 41 sites in United States
- Volunteers
- 1,026 people
- Sponsor
- Pfizer
Migraine
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of…
- Trial name
- NCT06401642
- Testing
- Zavegepant
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Migraine Disorders
Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache
Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS in patients with a single acute migraine attack with or without aura
- Trial name
- NCT02198339
- Testing
- BIBN 4096 BS
- Volunteers
- 126 people
- Sponsor
- Boehringer Ingelheim
Migraine Headache
Zomig - Treatment of Acute Migraine Headache in Adolescents
The purpose of this study is to investigate if Zomig® Nasal Spray will help children (age 12-17 years) with migraine headaches feel better.
- Trial name
- TEENZ (NCT01211145)
- Testing
- Zolmitriptan
- Where
- 74 sites in United States, Estonia and 6 more
- Volunteers
- 1,653 people
- Sponsor
- AstraZeneca
Migraine
Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)
The purpose of this study is to investigate the safety and tolerability of telcagepant (MK-0974) in the long-term treatment of acute migraine in adult participants.
- Trial name
- NCT00443209
- Testing
- Telcagepant 300 mg soft gel capsules, Telcagepant 280 mg tablets, Rizatriptan 10 mg tablets
- Volunteers
- 1,068 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Migraine
Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine
This study is intended to evaluate the efficacy and safety of Nerivio, an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine, for the acute treatment of migraine in people with…
- Trial name
- NCT04161807
- Testing
- Nerivio
- Where
- 2 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- Theranica
Acute Migraine
Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine
This is a randomized, double-blind, multi-center, parallel-group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo.
- Trial name
- Zotrip (NCT02745392)
- Testing
- ZP-Zolmitriptan
- Where
- 36 sites in United States
- Volunteers
- 365 people
- Sponsor
- Zosano Pharma Corporation
Migraine
Intravenous Metoclopramide Versus Dexketoprofen Trometamol Versus Metoclopramide+ Dexketoprofen Trometamol in Migraine
Acute headache is one of the most common reasons for presentation to the emergency department (ED), accounting for 2-3% of all emergency visits.
- Trial name
- NCT04252521
- Testing
- metoclopramide, dexketoprofen trometamol, metoclopramide+dexketoprofen trometamol
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Adiyaman University Research Hospital
Migraine Disorders
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
The purpose of this study is to evaluate the efficacy and safety of a range of doses of oral sumatriptan for the acute treatment of migraine in children ages 10 to 17.
- Trial name
- NCT00963937
- Testing
- Sumatriptan 25 mg, Sumatriptan 50 mg
- Where
- 16 sites in Japan
- Volunteers
- 178 people
- Sponsor
- GlaxoSmithKline
Migraine, With or Without Aura
Trial in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.
- Trial name
- NCT03461757
- Testing
- Rimegepant
- Where
- 69 sites in United States
- Volunteers
- 1,811 people
- Sponsor
- Pfizer
Migraine
ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine
Research question and objectives Primary endpoint To evaluate the effectiveness of Rimegepant in the acute treatment of migraine as measured by most severe pain, onset of pain relief, satisfaction with pain relief, and…
- Trial name
- NCT06439628
- Testing
- Rimegepant
- Where
- 3 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Chinese PLA General Hospital
Acute Migraine Headache
Comparison of Oral Paracetamol and Zolmitriptan Efficacy in the Treatment of Acute Migraine in Emergency Department
Migraine is a chronic and sometimes progressive disorder, characterized by headache, recurrent episodes, and other associated symptoms.
- Trial name
- NCT03145467
- Testing
- Paracetamol, Zolmitriptan
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Pamukkale University
Migraine Headache
Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine
The study is being conducted to determine if OPTINOSE SUMATRIPTAN delivered nasally (through the nose) using the OPTINOSE SUMATRIPTAN Device can reduce the pain and symptoms associated with migraine headaches.
- Trial name
- NCT01462812
- Testing
- Sumatriptan
- Where
- 15 sites in United States
- Volunteers
- 223 people
- Sponsor
- Optinose US Inc.
Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- Ubro Peds (NCT05125302)
- Testing
- Ubrogepant
- Where
- 129 sites in United States, Puerto Rico
- Volunteers
- 1,059 people
- Sponsor
- AbbVie
Migraine
Oral Dexamethasone for the Treatment of Acute Migraine Recurrence in the Pediatric Emergency Department
Migraine recurrence is common amongst pediatric patients being discharged from the emergency department after treatment for migraine.
- Trial name
- NCT02794441
- Testing
- Dexamethasone
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Children's Hospital of Eastern Ontario
Migraine
A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine
The purpose of this study is: 1. To compare the efficacy of a single dose of Frovatriptan 2.5 mg with that of placebo in acute treatment of up to one migraine attract 2. To assess recurrence rate between two group 3.
- Trial name
- NCT00821483
- Testing
- Frovatriptan
- Volunteers
- 298 people
- Sponsor
- SK Chemicals Co., Ltd.
Migraine Headaches
To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches
to demonstrate the superiority of Trexima (combination of sumatriptan as the succinate 85 mg and naproxen sodium 500 mg) versus placebo in the acute treatment of migraine to demonstrate the superiority of Trexima versus the…
- Trial name
- NCT00434083
- Testing
- sumatriptan, naproxen sodium
- Where
- 2 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- POZEN